Zimmer Biomet Holdings, Inc. Q4 2024 Earnings Conference Call Overview
Company Participants:
David DeMartino
Senior Vice President-Investor Relations
Ivan Tornos
President and Chief Executive Officer
Suketu Upadhyay
CFO and EVP, Finance, Operations and Supply Chain
Conference Call Participants:
Robbie Marcus – JPMorgan
Patrick Wood – Morgan Stanley
Steven Lichtman – Oppenheimer and Company
Matt Taylor – Jefferies
David Roman – Goldman Sachs
Vik Chopra – Wells Fargo
Ryan Zimmerman – BTIG
Danielle Antalffy – UBS
Travis Steed – Bank of America
Rick Wise – Stifel
Matt Miksic – Barclays
Jayson Bedford – Raymond James
Operator: Good morning, ladies and gentlemen, and welcome to the Zimmer Biomet Fourth Quarter 2024 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded today, February 06, 2025.
During the conference call, company executives discussed the financial results for the fourth quarter of 2024. Ivan Tornos, President and Chief Executive Officer, highlighted the company’s achievements and future growth strategies. Suketu Upadhyay, CFO, provided financial insights and operational updates. Overall, the company reported strong performance and outlined plans for continued success in the upcoming year.
Investment analysts participating in the call asked relevant questions and gained valuable insights into Zimmer Biomet’s financial health and market position. The interactive session provided a platform for stakeholders to understand the company’s trajectory and make informed decisions.
Overall, the Q4 2024 Earnings Conference Call showcased Zimmer Biomet’s commitment to transparency, accountability, and stakeholder engagement. The company’s leadership team demonstrated expertise and vision, setting a positive tone for future growth and innovation.
How this will affect me:
The Q4 2024 Earnings Conference Call by Zimmer Biomet provides valuable information for investors like myself. By understanding the company’s financial performance and strategic direction, I can make informed decisions about my investments in Zimmer Biomet. The insights gained from the conference call help me assess the company’s growth potential and long-term prospects, guiding my investment strategies.
How this will affect the world:
As a global leader in the medical technology industry, Zimmer Biomet’s performance and strategic decisions have a significant impact on the healthcare sector and patients worldwide. The insights shared during the Q4 2024 Earnings Conference Call provide stakeholders with a clear understanding of the company’s contributions to advancements in healthcare technology, innovation, and patient care. Zimmer Biomet’s continued success and growth have the potential to drive positive change and improve healthcare outcomes on a global scale.
Conclusion:
The Zimmer Biomet Q4 2024 Earnings Conference Call was a significant event that showcased the company’s financial performance, strategic direction, and commitment to stakeholders. The insights shared during the call provide valuable information for investors, analysts, and the global healthcare community. Zimmer Biomet’s leadership team demonstrated expertise, transparency, and vision, setting a positive tone for future growth and innovation. Overall, the conference call highlighted Zimmer Biomet’s position as a key player in the medical technology industry with a focus on driving positive change and improving healthcare outcomes worldwide.
